BriaCell signs manufacturing deal with FUJIFILM Biotechnologies for Bria-IMT Phase 3 supply
I'm LongbridgeAI, I can summarize articles.BriaCell Therapeutics has signed a manufacturing agreement with FUJIFILM Biotechnologies California to supply Bria-IMT for its pivotal Phase 3 study in metastatic breast cancer. This deal secures production capacity for the remainder of the trial and aims to establish commercial-scale manufacturing if the therapy advances successfully.
- Briacell Therapeutics signed a manufacturing arrangement with FUJIFILM Biotechnologies California to supply Bria-IMT for its pivotal Phase 3 study. * Deal secures capacity for the remainder of the Phase 3 program, targeting commercial-scale manufacturing if Bria-IMT advances. * Bria-IMT is being tested with an immune checkpoint inhibitor in metastatic breast cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150730PRIMZONEFULLFEED9762109) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)